REGENXBIO has settled its patent infringement litigation with Sarepta Therapeutics, receiving a $39 million payment and agreeing not to sue Sarepta over its ELEVIDYS product and AAVrh74-based capsids. This resolution removes a significant legal overhang for both companies, providing clarity on intellectual property rights related to gene therapies.
REGENXBIO and the University of Pennsylvania have settled their patent infringement lawsuit against Sarepta Therapeutics and Catalent. Sarepta will pay REGENXBIO $39 million, and all ongoing litigation regarding the '617 and '274 patents will be terminated with prejudice. This agreement includes a covenant not to sue Sarepta for future claims related to ELEVIDYS and AAVrh74-based capsids, providing Sarepta with intellectual property certainty for its key gene therapy product. For REGENXBIO, the settlement provides a financial boost and removes the cost and uncertainty of ongoing litigation. This is a positive development for both companies, as it resolves a significant legal dispute and allows them to focus on their core business operations. The short-term impact for RGNX is the cash infusion, while for SRPT, it's the removal of a legal overhang. Long-term, it clarifies the IP landscape for AAVrh74-based gene therapies.